Zydus Lifesciences Advances Pembrolizumab Biosimilar Toward USFDA Filing
Filing Summary
Zydus Lifesciences Ltd has announced the successful clinical development of its Pembrolizumab biosimilar, FYB206, marking progress toward a USFDA filing. The pivotal pharmacokinetic study demonstrated bioequivalence with Keytruda®, a leading oncology drug. Zydus has in-licensed FYB206 from Formycon AG for the U.S. and Canadian markets. The company is preparing regulatory dossiers for a Biologics License Application. This development positions Zydus as a potential new entrant in the North American immuno-oncology biosimilar market, following the expiration of Keytruda®’s exclusivity.
Zydus Lifesciences Ltd has announced the successful clinical development of its Pembrolizumab biosimilar, FYB206. The pivotal pharmacokinetic study demonstrated pharmacokinetic equivalence with Keytruda®, a leading oncology drug. Zydus has in-licensed FYB206 from Formycon AG for exclusive distribution in the U.S. and Canadian markets. This development marks a significant milestone toward filing for regulatory approval with the USFDA.
The financial terms of the in-licensing agreement with Formycon AG have not been disclosed. However, the agreement grants Zydus exclusive rights to market FYB206 in the U.S. and Canada. The successful completion of the pivotal study supports the planned Biologics License Application (BLA) filing with the USFDA, positioning Zydus as a potential first-wave filer in the North American market.
The scope of the clinical development involved a randomized, double-blind, multi-centre pharmacokinetic study. The study’s primary objective was to demonstrate the bioequivalence of FYB206 with Keytruda®. The study’s success allows Zydus to proceed with the preparation of regulatory dossiers. The company is focusing on completing all necessary development activities to finalize documents for regulatory approval.
In the context of the oncology market, Pembrolizumab is a humanized monoclonal antibody used to treat various tumors. Keytruda®, the reference drug, achieved global sales of USD 31.6 billion in 2025. The substantial demand for oncology treatments underscores the market potential for biosimilars like FYB206. Zydus’s entry into the North American immuno-oncology biosimilar market aligns with its strategic focus on expanding access to affordable oncology treatments.
The timeline for the regulatory process involves close collaboration with regulatory authorities. Zydus aims to make FYB206 available following the expiration of Keytruda®’s exclusivity. The company is preparing for a near-term BLA filing with the USFDA, which is a critical step toward market entry.
Formycon AG is a leading developer of biosimilars, focusing on creating affordable alternatives to high-cost biologics. The company’s collaboration with Zydus Lifesciences Ltd reflects its strategic goal to expand its presence in the North American market through partnerships.
Zydus Lifesciences Ltd is an innovation-led life-sciences company with a global presence. The company focuses on pharmaceuticals and consumer wellness, supported by an emerging MedTech franchise. Zydus is committed to unlocking new possibilities in life sciences through quality healthcare solutions.